Ousia Pharma ApS
Private limited companyCVR 43055909København NActive
Ousia Pharma ApS is a private limited company, based in København N, active in research and experimental development on natural sciences and engineering, founded in 2022. The company made a loss in both 2024 and 2025, most recently DKK 12.8m. 8 other companies in the database are registered at the same address.
Key figures · financial year 2025
Gross profit−DKK 10.2m−179.1% vs. 2024
Net profit−DKK 12.8m−138.9% vs. 2024
EquityDKK 11.8m+217.2% vs. 2024
Employees8latest month from CVR
What has changed
calculated from recorded figures and datesFinancials: 2025 against 2024
- The loss grew: from DKK 5.3m to DKK 12.8m (2024 → 2025).
- Equity turned positive again: DKK 11.8m (2024 → 2025).
Employees
- 4 more employees than a year earlier: 8 (07/2026) against 4 (07/2025).
Management and owners, last 24 months
- New in management: Otello Stampacchia (board member, 27/03/2025), Menelas Nicolas Pangalos (board member, 27/03/2025) and Ramesh Rajanikant Bhatt (board member, 31/07/2026) (+2).
- Stepped down: Ian Rodney Laquian (chair of the board, 31/07/2026), Mikael Søndergaard Thomsen (board member, 27/03/2025) and Jeppe Ragnar Andersen (board member, 27/03/2025) (+5).
- New owners registered: JLSa2 Therapeutics, Inc. (31/07/2026), BioInnovation Institute Fonden (27/03/2025) and Science Studio Holding ApS (27/03/2025) (+8).
- No longer registered as owner: Science Studio Holding ApS (26/03/2025), Nordic Alchemy Holding ApS (26/03/2025) and Klein Science Holding ApS (26/03/2025) (+10).
Registrations, last 24 months
- 31/07/2026: Share capital changed from 61,897 DKK to 99,583 DKK
- 27/03/2025: Share capital changed from 40,002 DKK to 61,897 DKK
- 01/01/2025: Industry changed to Research and experimental development on natural sciences and engineering (721000)
Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.
Financial statements
Financial years 2022–2025 · amounts in DKK thousandEquity and net profit
| 2022 | 2023 | 2024 | 2025 | Change | |
|---|---|---|---|---|---|
| Revenue | not stated | not stated | not stated | not stated | – |
| Gross profit | −645 | −2,240 | −3,656 | −10,205 | −179.1% |
| Operating profit (EBIT) | −1,095 | −4,304 | −5,672 | −14,414 | −154.1% |
| Profit before tax | −1,205 | −4,536 | −6,181 | −14,862 | −140.4% |
| Net profit | −904 | −3,747 | −5,349 | −12,778 | −138.9% |
| Total assets | 3,280 | 5,798 | 5,090 | 12,498 | +145.5% |
| Equity | −864 | −4,738 | −10,087 | 11,818 | +217.2% |
| Liabilities | 4,144 | 10,537 | 15,177 | 680 | −95.5% |
| Cash and cash equivalents | 2,778 | 4,901 | 3,901 | 10,198 | +161.4% |
| Average number of employees | 3 | 5 | 6 | 8 | +33.3% |
Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.
Download the figures as CSV · free with an account, amounts in whole DKK
Signals from the financial statements
calculated from the 2025 figuresLoss for 4 years in a row
Net result has been negative in 2022–2025.
How is this calculated?
Net result is negative in the two or more latest annual reports in a row.
The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.
Annual reports
4 financial years| Financial year | Period | Published | Figures for | Documents |
|---|---|---|---|---|
| 2025 | 01/01/2025 – 31/12/2025 | 02/07/2026 | The company | PDF not statedXBRL |
| 2024 | 01/01/2024 – 31/12/2024 | 19/06/2025 | The company | PDFXBRL |
| 2023 | 01/01/2023 – 31/12/2023 | 29/06/2024 | The company | PDFXBRL |
| 2022 | 14/02/2022 – 31/12/2022 | 29/03/2023 | The company | PDF not statedXBRL |
The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.
Employees
monthly figures from CVRPosition in the industry
431 companies in the databaseComparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.
Gross profit−DKK 10.2mNo. 391 of 421
Better than 7% of the companies in the industry
EquityDKK 11.8mNo. 134 of 431
Better than 69% of the companies in the industry
Number of employees8No. 158 of 431
Better than 63% of the companies in the industry
Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.
Compared with similar companies
size, age and company form| Group | Gross profit | Equity |
|---|---|---|
| Companies with fewer than 20 employees69,967 companies in the comparison | No. 69,644of 69,742 Better than 0% | No. 8,126of 69,964 Better than 88% |
| Same industry and fewer than 20 employees329 companies in the comparison | No. 307of 323 Better than 5% | No. 60of 329 Better than 82% |
| Companies that are founded within the last five years16,662 companies in the comparison | No. 16,581of 16,614 Better than 0% | No. 780of 16,661 Better than 95% |
| All companies of type ApS66,508 companies in the comparison | No. 66,287of 66,379 Better than 0% | No. 6,109of 66,505 Better than 91% |
The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.
Compare with the industry
Research and experimental development on natural sciences and engineeringGross profit
- Ousia Pharma ApS−DKK 10.2m
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
Net profit
- Ousia Pharma ApS−DKK 12.8m
- Carlsberg A/SDKK 7bn
- Zealand Pharma A/SDKK 6.5bn
Equity
- Ousia Pharma ApSDKK 11.8m
- Carlsberg A/SDKK 30.7bn
- Zealand Pharma A/SDKK 14.8bn
Employees
- Ousia Pharma ApS8
- Carlsberg A/S107
- Zealand Pharma A/S569
Latest financial year per company. Choose up to three companies from the largest in the industry.
Owners and group
from the Public Ownership RegisterOwners
- JLSa2 Therapeutics, Inc.100%
Ousia Pharma ApS
Management
7 active registrationsExecutive management
| Name | Role | Appointed |
|---|---|---|
| Christoffer Clemmensen | Director | 14/02/2022 |
| Jonas Odgaard Petersen | Director | 14/02/2022 |
| Anders Bue Klein | Director | 14/02/2022 |
Board of directors
| Name | Role | Appointed |
|---|---|---|
| Otello Stampacchia | Board member | 27/03/2025 |
| Menelas Nicolas Pangalos | Board member | 27/03/2025 |
| Ramesh Rajanikant Bhatt | Board member | 31/07/2026 |
| Gaurav Gupta | Chair of the board | 31/07/2026 |
- Founders
- Science Studio Holding ApS, Nordic Alchemy Holding ApS, Klein Science Holding ApS
Former management (8)
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| Ian Rodney Laquian | Chair of the board | 14/02/2023 | 31/07/2026 |
| Mikael Søndergaard Thomsen | Board member | 14/02/2023 | 27/03/2025 |
| Jeppe Ragnar Andersen | Board member | 14/02/2023 | 27/03/2025 |
| Morten Peltola Toft | Board member | 14/02/2023 | 27/03/2025 |
| Christoffer Clemmensen | Board member | 14/02/2023 | 31/07/2026 |
| Jonas Odgaard Petersen | Board member | 14/02/2023 | 27/03/2025 |
| Anders Bue Klein | Board member | 14/02/2023 | 27/03/2025 |
| Margareta Elisabeth Björk | Board member | 27/03/2025 | 31/07/2026 |
Signing rule: Selskabet tegnes af bestyrelsesformanden sammen med to bestyrelsesmedlemmer eller af den samlede bestyrelse i forening.
Address and production units
1 active production unitsOle Maaløes Vej 3
2200 København N
København Municipality · Postcode 2200
Other companies at the address (8)
- BII Holdings A/SOther financial service activities n.e.c.
- Skape Bio ApSResearch and experimental development on natural sciences and engineering
- Agrobiomics ApSResearch and experimental development on natural sciences and engineering
- Tetrakit Technologies ApSResearch and experimental development on natural sciences and engineering
- BioColor ApSResearch and experimental development on natural sciences and engineering
| Production unit | Address | Employees | P number |
|---|---|---|---|
| Ousia Pharma ApS | Ole Maaløes Vej 3, 2200 København N | 5 | 1027996171 |
Purpose
Formål er at udvikle nye lægemiddelkandidater til behandling af kroniske sygdomme.
The purpose is quoted from the register in Danish.
Changes year by year
59 registered events82022
82023
12024
212025
212026
202621 changescapital 1 · management 5 · ownership 14 · accounts 1
- CapitalShare capital changed from 61,897 DKK to 99,583 DKK
- ManagementRamesh Rajanikant Bhatt appointed board member
- ManagementGaurav Gupta appointed chair of the board
- ManagementMargareta Elisabeth Björk stepped down as board member
- ManagementIan Rodney Laquian stepped down as chair of the board
- ManagementChristoffer Clemmensen stepped down as board member
- OwnershipOmega Fund VIII, L.P registered as owner (33.33%)
- OwnershipOmega Fund VIII, L.P is no longer registered as owner
- OwnershipKlein Science Holding ApS registered as owner (10%)
- OwnershipKlein Science Holding ApS is no longer registered as owner
- OwnershipScience Studio Holding ApS registered as owner (10%)
- OwnershipScience Studio Holding ApS is no longer registered as owner
- OwnershipNordic Alchemy Holding ApS registered as owner (10%)
- OwnershipNordic Alchemy Holding ApS is no longer registered as owner
- OwnershipJLSa2 Therapeutics, Inc. registered as owner (100%)
- OwnershipBII Holdings A/S is no longer registered as owner
- OwnershipOmega Fund VIII, L.P is no longer registered as owner
- OwnershipScience Studio Holding ApS is no longer registered as owner
- OwnershipNordic Alchemy Holding ApS is no longer registered as owner
- OwnershipKlein Science Holding ApS is no longer registered as owner
- AccountsAnnual report for 2025 published
202521 changesaccounts 1 · ownership 10 · capital 1 · management 8 · industry 1
- AccountsAnnual report for 2024 published
- OwnershipBII Holdings A/S registered as owner (5%)
- OwnershipBioInnovation Institute Fonden is no longer registered as owner
- CapitalShare capital changed from 40,002 DKK to 61,897 DKK
- ManagementMargareta Elisabeth Björk appointed board member
- ManagementOtello Stampacchia appointed board member
- ManagementMenelas Nicolas Pangalos appointed board member
- ManagementJonas Odgaard Petersen stepped down as board member
- ManagementAnders Bue Klein stepped down as board member
- ManagementMikael Søndergaard Thomsen stepped down as board member
- ManagementMorten Peltola Toft stepped down as board member
- ManagementJeppe Ragnar Andersen stepped down as board member
- OwnershipOmega Fund VIII, L.P registered as owner (15%)
- OwnershipBioInnovation Institute Fonden registered as owner (10%)
- OwnershipScience Studio Holding ApS registered as owner (15%)
- OwnershipNordic Alchemy Holding ApS registered as owner (15%)
- OwnershipKlein Science Holding ApS registered as owner (15%)
- OwnershipScience Studio Holding ApS is no longer registered as owner
- OwnershipKlein Science Holding ApS is no longer registered as owner
- OwnershipNordic Alchemy Holding ApS is no longer registered as owner
- IndustryIndustry changed to Research and experimental development on natural sciences and engineering (721000)
20241 changeaccounts 1
- AccountsAnnual report for 2023 published
20238 changesaccounts 1 · management 7
- AccountsAnnual report for 2022 published
- ManagementJonas Odgaard Petersen appointed board member
- ManagementAnders Bue Klein appointed board member
- ManagementIan Rodney Laquian appointed chair of the board
- ManagementMikael Søndergaard Thomsen appointed board member
- ManagementMorten Peltola Toft appointed board member
- ManagementChristoffer Clemmensen appointed board member
- ManagementJeppe Ragnar Andersen appointed board member
20228 changesname 1 · founded 1 · management 3 · ownership 3
- NameName changed from Ouisa Pharma ApS to Ousia Pharma ApS
- FoundedRegistered as Ouisa Pharma ApS
- ManagementChristoffer Clemmensen appointed director
- ManagementJonas Odgaard Petersen appointed director
- ManagementAnders Bue Klein appointed director
- OwnershipScience Studio Holding ApS registered as owner (33.33%)
- OwnershipKlein Science Holding ApS registered as owner (33.33%)
- OwnershipNordic Alchemy Holding ApS registered as owner (33.33%)
Related companies
Same industry in København
- Genmab A/S676 employees
- 3shape A/S518 employees
- Carlsberg A/S107 employees
- IQVIA RDS Denmark A/S100 employees
- Nuevolution A/S100 employees
- Sunshine Enterprise Holding A/S73 employees
Same people in management
- GN Hearing A/Svia Morten Peltola Toft
- FalCom A/Svia Morten Peltola Toft
- Sanos Group ApSvia Jeppe Ragnar Andersen
- Sanos A/Svia Jeppe Ragnar Andersen
- Natus Medical Denmark ApSvia Morten Peltola Toft
- Contera Pharma A/Svia Mikael Søndergaard Thomsen
Largest in the industry
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Gubra A/SDKK 2.6bn
- Vestas Wind Systems A/SDKK 2.5bn
- Bang & Olufsen A/SDKK 1.4bn
- 3shape A/SDKK 1.3bn
Source and updates
The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026.